ESTRO 2022 - Abstract Book

S1056

Abstract book

ESTRO 2022

Results A total of 120 lung cancer survivors were included in the study, of which 40 of them referred severe fatigue. Results are presented in the following table:

Conclusion Lung cancer survivors with a severe radiotherapy-related fatigue referred a worse perceived-health status compared to lung cancer survivors without a severe radiotherapy-related fatigue one year after radiotherapy treatment.

PO-1252 Treatment patterns and prognosis in inoperable stage III NSCLC treated with concurrent CRT +/- ICI

B. Flörsch 1 , J. Taugner 1 , L. Käsmann 1 , S. Kenndoff 1 , J. Guggenberger 1 , A. Tufman 2 , N. Reinmuth 3 , T. Duell 3 , C. Belka 1 , C. Eze 1 , F. Manapov 1 1 University Hospital, LMU Munich, Department of Radiotherapy and Radiation Oncology, Munich, Germany; 2 University Hospital, LMU Munich, Department of Internal Medicine V, Munich, Germany; 3 Asklepios Lung Clinic, Department of Oncology, Munich-Gauting, Germany Purpose or Objective To investigate the impact of treatment developments on outcome in patients with inoperable stage III non-small cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy (cCRT) +/- immune checkpoint inhibition (ICI) between 2011 and 2020. Materials and Methods All consecutive patients treated in a single tertiary cancer centre were included. Patients were stratified by treatment year and divided into three subgroups: 2011–2014, 2015–2017 and 2018–2020. Patient- and treatment-related characteristics, including use of ICI, radiation technique, PTV>700cc and total lung V20 of more than 30% (V20MED30) were analysed. Planning target volume (PTV) included primary tumor, involved nodes and safety margins. The primary endpoints were progression-free (PFS) and overall-survival (OS). All survival parameters were calculated from the last day of cCRT. Results In total, 136 consecutive patients were included. Median follow-up (FU) was 35.7 (range: 0.9–111.9) months; median age was 66.9 (range: 48.9–82.5) years; 93 (68%) were male. Fifty-six (41%) patients had squamous-cell-carcinomas and 69 (51%) adenocarcinomas. All patients completed conventionally fractionated cCRT to a total dose ≥ 60.0 Gy; 82 (60%) received VMAT, while 35 (26%) received three-dimensional conformal radiotherapy (3D-CRT). Median PTV was 700 cc (range: 172.5–2293.2). Thirty-six (26%) patients received additional ICI with either durvalumab or nivolumab. The median PFS in the 2011-2014, 2015-2017 and 2018-2020 subgroups was 8.0 (range: 0.7 – 111.9), 8.2 (range: 0.4 – 55.0) and 26.3 (range: 0.9 – 37.9) months, respectively (p = 0.006). The median OS for patients treated from 2011- 2014 and 2015-2017 was 19.9 (range 0.7 – 111.9) and 23.4 (range: 2.5 – 69.4) months, while it was not reached for patients treated between 2018 and 2020. In the univariate analysis, ICI application was a significant prognosticator for PFS (p = 0.002) and OS (p = 0.001). Similarly, radiotherapy in VMAT technique was associated with significantly improved PFS (p = 0.001) and OS (p = 0.001), while PTV>700cc (p = 0.011) and V20MED30 (p = 0.030) were also significant prognosticators for shorter PFS and PTV>700cc (p = 0.001), ≥ 20 pack-years (p = 0.029) and V20MED30 (p = 0.002) were significantly associated with worse OS. In the multivariate analysis, only PTV>700cc remained a significant prognosticator of PFS (p = 0.038). However, a clear trend for ICI was observed (p = 0.059). Furthermore, PTV>700cc (p = 0.003), V20MED30 (p = 0.015), ≥ 20 pack-years and ICI (p = 0.032) remained significantly associated with OS.